Phosphatidylethanolamine binding protein-4 (PEBP4) is increased in IgA nephropathy and is associated with IgA-positive B-cells in affected kidneys by Taylor, Scott et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2019
Phosphatidylethanolamine binding protein-4 (PEBP4) is increased in IgA
nephropathy and is associated with IgA-positive B-cells in affected kidneys
Taylor, Scott ; Pieri, Kyriaki ; Nanni, Paolo ; Tica, Jure ; Barratt, Jonathan ; Didangelos, Athanasios
Abstract: IgA nephropathy (IgAN) is the most common glomerulonephritis worldwide and a major cause
of chronic kidney disease and failure. IgAN is driven by an autoimmune reaction against galactose-
deficient IgA1 that results in the generation of autoantibodies and large IgG-IgA immune complexes.
Immune complexes accumulate in the glomerular mesangium causing chronic inflammation and renal
scarring. A significant proportion of IgAN patients develop end-stage kidney disease and require dialysis
or transplantation. Currently, there are no approved specific therapies that can ameliorate the systemic
autoimmune reaction in IgAN and no biomarkers that can predict renal inflammation and scarring. In
this study, we used shotgun LC-MS/MS proteomics to compare small volumes of urine from healthy
subjects and IgAN patients. We identified multiple urine proteins with unknown renal or IgAN function.
Our attention was captured by the increase of phosphatidylethanolamine binding protein-4 (PEBP4) in
IgAN urine. The function of PEBP4 in IgAN or renal disease is unknown. Increased levels of urine and
serum PEBP4 were subsequently validated in different cohorts of IgAN patients and PEBP4 was linked
to declining kidney function in IgAN. Strong PEBP4 staining was sporadically seen in IgAN kidney
biopsies, colocalising with IgA in glomeruli and in the lumen of kidney tubules. In a small number of
IgAN biopsies, PEBP4 colocalised with IgA and CD19 while the increased excretion of PEBP4 in IgAN
urine was accompanied by increased excretion of classic B-cell factors BAFF, BCMA and TACI as well
as IgA and IgG. PEBP4 is a new IgAN-related protein with unknown function and a likely renal disease
marker in urine and serum.
DOI: https://doi.org/10.1016/j.jaut.2019.102309
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-184633
Journal Article
Published Version
 
 
The following work is licensed under a Creative Commons: Attribution-NonCommercial-NoDerivatives
4.0 International (CC BY-NC-ND 4.0) License.
Originally published at:
Taylor, Scott; Pieri, Kyriaki; Nanni, Paolo; Tica, Jure; Barratt, Jonathan; Didangelos, Athanasios (2019).
Phosphatidylethanolamine binding protein-4 (PEBP4) is increased in IgA nephropathy and is associated
with IgA-positive B-cells in affected kidneys. Journal of autoimmunity, 105:102309.
DOI: https://doi.org/10.1016/j.jaut.2019.102309
Contents lists available at ScienceDirect
Journal of Autoimmunity
journal homepage: www.elsevier.com/locate/jautimm
Phosphatidylethanolamine binding protein-4 (PEBP4) is increased in IgA
nephropathy and is associated with IgA-positive B-cells in affected kidneys
Scott Taylor, Kyriaki Pieri, Paolo Nanni, Jure Tica, Jonathan Barratt, Athanasios Didangelos∗
University of Leicester, Mayer IgA Nephropathy Laboratory, University Road, LE1 7RH, Leicester, United Kingdom
A R T I C L E I N F O
Keywords:
IgA nephropathy (IgAN)
PEBP4
Urine
Proteomics
Biomarker
B-Cells
A B S T R A C T
IgA nephropathy (IgAN) is the most common glomerulonephritis worldwide and a major cause of chronic kidney
disease and failure. IgAN is driven by an autoimmune reaction against galactose-deficient IgA1 that results in the
generation of autoantibodies and large IgG-IgA immune complexes. Immune complexes accumulate in the
glomerular mesangium causing chronic inflammation and renal scarring. A significant proportion of IgAN pa-
tients develop end-stage kidney disease and require dialysis or transplantation. Currently, there are no approved
specific therapies that can ameliorate the systemic autoimmune reaction in IgAN and no biomarkers that can
predict renal inflammation and scarring. In this study, we used shotgun LC-MS/MS proteomics to compare small
volumes of urine from healthy subjects and IgAN patients. We identified multiple urine proteins with unknown
renal or IgAN function. Our attention was captured by the increase of phosphatidylethanolamine binding pro-
tein-4 (PEBP4) in IgAN urine. The function of PEBP4 in IgAN or renal disease is unknown. Increased levels of
urine and serum PEBP4 were subsequently validated in different cohorts of IgAN patients and PEBP4 was linked
to declining kidney function in IgAN. Strong PEBP4 staining was sporadically seen in IgAN kidney biopsies,
colocalising with IgA in glomeruli and in the lumen of kidney tubules. In a small number of IgAN biopsies, PEBP4
colocalised with IgA and CD19 while the increased excretion of PEBP4 in IgAN urine was accompanied by
increased excretion of classic B-cell factors BAFF, BCMA and TACI as well as IgA and IgG. PEBP4 is a new IgAN-
related protein with unknown function and a likely renal disease marker in urine and serum.
1. Introduction
IgA Nephropathy (IgAN) is a disease with autoimmune etiology and
the most common primary glomerulonephritis worldwide affecting ~1-
million people and a major cause of chronic nephropathy and kidney
failure [1]. The disease is caused by the production of aberrantly gly-
cosylated (galactose-deficient) immunoglobulin-A1 (IgA1) by activated
B-cells present in the bone marrow [2]. Abnormal O-glycosylation of
IgA, triggers the generation of autoantibodies and results in the for-
mation of circulating immune-complexes containing galactose-deficient
IgA1 plus autoreactive IgA and IgG. IgAN is associated with higher le-
vels of serum IgA, galactose-deficient IgA1 [3,4] and IgA-IgG immune-
complexes where IgA1 is the predominant subclass [5] while IgG2 has
been shown to be positively correlated with elevated serum IgA in IgAN
patients [6]. While the formation of anti-IgA immune-complexes is a
systemic autoimmune reaction and there is no primary renal abnorm-
ality, the kidney is affected by chronic accumulation of these large,
immune-complexes on the mesangium [7]. In response, mesangial cells
undergo classic inflammatory and fibroproliferative activation. This
cellular response is subtle and persistent and drives localised in-
flammation with infiltration of macrophages involved in tissue re-
modeling, as well as B- and T-cells targeting the IgA autoantigens [8].
Ultimately, IgA immune-complex-mediated inflammation drives glo-
merular and tubulointerstitial scarring with podocyte and proximal
tubule cell injury [7,9]. The pathogenesis of IgAN remains obscure and
our understanding of how IgA immune-complexes drive inflammation
and tissue remodeling is also limited [10]. Other than generic treatment
of hypertension and inhibition of the rennin-angiotensin system, there
are no specific (non-experimental) therapies that can prevent either the
generation of galactose-deficient IgA or the autoimmune reaction and
concomitant renal inflammation and scarring caused by immune-com-
plexes [11]. As a result, around 20% of IgAN patients develop renal
failure and require dialysis or transplantation [1]. Diagnosis and risk
stratification in IgAN are currently based on a kidney biopsy, which
carries significant morbidity and there are no serum or urine markers
with sufficient specificity to diagnose IgAN or predict which patients
might progress to kidney failure [12,13].
In an attempt to identify unknown bioactive proteins and possible
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disease markers in IgAN urine, we set out to develop clinically-relevant
proteomics methodology using very small volumes of patient urine and
optimized simple biochemical processing. During methodology opti-
misation for shotgun urine proteomics, we discovered an increase in
phosphatidylethanolamine binding protein-4 (PEBP4) in IgAN urine.
The biological function of PEBP4, first discovered in 2004 [14], is in-
completely understood and has been scarcely studied in different can-
cers [15]. Nothing is known about its expression and possible function
in IgAN or in the kidney. The discovery and upregulation of PEBP4 in
IgAN urine as well as its apparent relationship with IgA and B-cells in
the kidney is described here for the first time.
2. Materials and methods
2.1. Urine processing for proteomics analysis
During proteomics methodology optimisation, we compared 2 urine
pools generated from an initial cohort of 16 healthy subjects, versus 2
pools generated from the urine of 16 biopsy-confirmed IgAN patients (2
pools of 8 urines for each group). Proteomics was used to screen the
urine proteome and obtain an explorative overview of differential
protein levels, rather than for extensive statistical analysis. We used
archived urine samples from the Leicester renal bioarchive for the in-
itial analysis. Urine samples were spun before storing to remove cells
and cellular debris. To improve the analytical depth and dynamic range
of proteomics, urines were filtered and desalted (7kD cut-off spin-col-
umns) followed by depletion of albumin and IgG using pre-packed
antibody-based depletion spin-columns (Thermo, top-2 depletion kit),
given that albumin and IgG are the major “contaminant” proteins in
chronic kidney disease urine. Please note that for subsequent validation
ELISA measurements the urine was not subject to albumin/IgG deple-
tion. Importantly, we used just 500 μl of lyophilised desalted/albumin-
depleted urine per LC-MS/MS replicate. Miniaturisation is key in
clinically-relevant studies aimed at extracting maximum information
with the least technical manipulation from potentially scarce or old
clinical samples. For proteomics analyses, 2 μg of desalted and al-
bumin/IgG-depleted urinary protein from each sample, were dissolved
in 45 μl of 100mM triethylammonium bicarbonate buffer, reduced with
2mM TCEP (tris-2-carboxyethyl-phosphine) and alkylated with 15mM
chloroacetamide. Protein digestion was performed adding 5 μl of
trypsin (100 ng/μl in 10mM HCl) and enhanced by using a microwave
instrument (Discover System, CEM) for 30min at 5W and 60 °C.
Samples were dried in a SpeedVac and dissolved in 20 μl of 0.1% formic
acid for LC-MS/MS analysis.
2.2. Liquid-chromatography tandem mass-spectrometry (LC-MS/MS) of
urine pools
3 μl (2 μg) of processed urine samples were injected on a
nanoAcquity UPLC (Waters) connected to a Q-Exactive mass spectro-
meter (Thermo) equipped with a Digital PicoView source (New
Objective). Solvent composition at the two channels was 0.1% formic
acid for channel A and 0.1% formic acid, 99.9% acetonitrile for channel
B. Peptides were trapped on a Symmetry (Waters) C18 trap-column
(5 μm, 180 μm×20mm) and separated on a BEH300 (Waters) C18
column (1.7 μm, 75 μm×150 μm) at a flow rate of 250 nl/min using a
gradient from 1% to 40% acetonitrile in 90min. The mass spectrometer
was operated in data-dependent mode (DDA), acquiring full-scan MS
spectra (350–1500m/z) at a resolution of 70,000 at 200m/z (mass to
charge) after accumulation to a target value of 3,000,000, followed by
HCD (high-energy collision dissociation) fragmentation on the 12 most
intense signals per MS cycle. HCD spectra were acquired at a resolution
of 35,000 using normalised collision energy of 25 and a maximum in-
jection time of 120ms. Automatic gain control (AGC) was set to 50,000
ions. Charge state screening was enabled and singly and unassigned
charge states were rejected. Only precursors with intensity above 8300
were selected for MS/MS (2% underfill ratio). Precursor masses pre-
viously selected for MS/MS were excluded from further selection for
30s, and the exclusion window was set at 10 ppm. The samples were
acquired using internal lock mass calibration on m/z 371.1010 and
445.1200. Acquired raw MS/MS files were converted to Mascot Generic
Format (.mgf) using ProteoWizard (http://proteowizard.sourceforge.
net/) and proteins were identified using the Mascot search engine
(Matrix Science, version 2.5.1.3.) searching data against the Swissprot
human database (version 2018-07-18). Carbamidomethylation of cy-
steine was set as fixed modification while methionine oxidation was set
as variable. Enzyme specificity was set to trypsin allowing a maximum
of two missed-cleavages. Precursor and fragment tolerance was set to
0.03Da and 10 ppm, respectively. The Mascot.dat file results were
loaded in Scaffold (Proteome Software) to validate peptide and protein
identifications, to visualize and count peptide and spectra identifica-
tions. The maximum false-discovery rate was set to 0.01 for peptides
and 0.05 for proteins. Only proteins identified with at least 2 peptides
were considered for follow up analysis. More information on pro-
teomics analysis can be found in previous work [16]. Protein-protein
interaction network analysis of genes and proteins was performed using
StringDB v11 and Cytoscape (v3.6.1). BinGO was used in Cytoscape to
identify Gene Ontology (GO) annotations.
2.3. Elisa
ELISA analysis was used to detect different proteins in urine as
described in Results. Urine was used at 1/10 dilution (10 μl of urine and
90 μl of ELISA diluent unless otherwise stated) and ELISAs were per-
formed using kit instructions and supplied reagents and standards in
duplicate. Please note that in contrast to the urine used for proteomics,
urine samples used for ELISA were not albumin/IgG-depleted. PEBP4,
CTSZ, and J-Chain were detected using kits from Abbexa. BAFF kit was
from Bio-Techne. BAFF-R, IFNG, TACI, BCMA and TGFB1 kits from
Abcam. IgA, IgG and secretory IgA (sIgA) were measured by custom-
made (in-house developed) ELISAs [17,18]. Briefly, human IgA, IgG
(both DAKO) or IgA secretory component (Sigma) rabbit antibodies,
were coated on Nunc MaxiSorp ELISA plates (1/1000 antibody in PBS)
for 24 h followed by 2 h blocking in 5% BSA. Coated plates were then
incubated with urine diluted 1/10 for IgA or 1/100 for IgG in PBS for
16 h at 4 °C, alongside NIBSC stock IgA and IgG standards (1mg/ml) in
serial dilutions using PBS. Following extensive washing in PBS with
tween-20, plates were covered with HRP-conjugated anti-human IgA
and IgG antibodies (DAKO) for 2 h, washed and developed using OPD
and stable peroxide substrate (Thermo) for 5min. ELISA Reactions were
stopped using 2M H2SO4 and immediately read at 492 nm. For the
custom-made secretory IgA ELISA [17], the procedure was identical to
the IgA ELISA described above but the plate was first coated with rabbit
antibodies (1/1000 dilution) against human secretory IgA component
(Sigma) for 24 h. Secretory IgA was detected using HRP-conjugated
anti-human IgA (DAKO) as above. For estimation of all different protein
levels in urine by ELISA, background absorbance was subtracted from
all standard and experimental sample absorbance values. No outliers
were removed. All urine ELISA concentrations were corrected to urine
creatinine to take into account renal filtration and urine concentration
[19]. Urine creatinine was detected using a colorimetric 96-well plate
kit and 5 μl of healthy or IgAN urine according to instructions (Quan-
tichromTM; BioAssay).
2.4. Fluorescence immunohistology
For tissue staining we used archived needle kidney biopsies with a
proven diagnosis of primary IgAN or biopsies reported as normal (from
healthy kidney transplant donors). We also used biopsies from patients
diagnosed with Lupus nephritis. Needle biopsies were fixed in 10%
formalin for 48 h before automated paraffin block embedding. Dried
blocks were then sectioned on a Leica microtome at 10 μm per section.
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Sections were treated using acid-based antigen retrieval and de-waxing
solution (Abcam) at 98 °C for 1 h. Sections were thoroughly washed,
blocked in 10% normal donkey serum (Dako) for 1 h and subsequently
incubated with primary antibodies: rabbit PEBP4, mouse CD64 and
mouse Vimentin from Abcam, goat IgA1 (Sigma) and mouse CD19
(BioTechne) at 1/100 dilution in 10% donkey serum for 16 h at 4 °C.
Sections were washed 4 times in PBS and then incubated with fluor-
escent secondary antibodies as described. Anti-rabbit 568 nm, anti-
mouse 488 nm or 647 nm and anti-goat 488 nm. Sections were washed
again 4 times and were covered in Vectashield anti-fade mounting so-
lution. Finally staining was visualised in a Zeiss Axioscope microscope
using a TissueFaxs stage and image scanning multispectral software
(TissueGnostics).
2.5. Gel electrophoresis immunoblotting and sample dot-blots
Immunoblotting against PEBP4 was performed on 1 million cells per
condition as described in Results. Cells were lysed in 0.2% SDS con-
taining proteinase inhibitors (Sigma), protein concentration was esti-
mated (A280nm) and samples were mixed with 4x Laemli sample buffer
and boiled at 98 °C for 10min. 20 μg of protein per sample were loaded
on 4–12% NuPAGE mini-gels (Thermo), proteins were transferred on
nitrocellulose membrane, blocked in 10% milk for 1 h and incubated in
rabbit PEBP4 antibodies (Abcam) diluted in 5% BSA at 1/500 dilution
for 16 h at 4 °C. Goat anti-myeloperoxidase (BioTechne) was used at the
same dilution. Membranes were washed 4 times in PBS-tween and in-
cubated with HRP-conjugated swine anti-rabbit or rabbit anti-goat an-
tibodies (Dako; 1/2000) for 1 h at room temperature. Membranes were
washed again 4 times in PBS-tween and exposed to ECL-prime devel-
oping reagent (Amersham). Finally, signals were visualised in a Bio-Rad
imaging system. Mouse beta-actin (Abcam) served as the loading con-
trol, detected with HRP-conjugated rabbit anti-mouse antibodies. Dot-
blots were performed on nitrocellulose membranes. 1 μl of urine was
used per dot. Membranes were air-dried for 1 h, blocked (10% milk in
PBS), incubated with PEBP4 and secondary HRP antibodies and de-
veloped as described above.
2.6. Human samples and specimens
Ethical approval for this study and for collection of biofluids was
obtained from the Northamptonshire, Leicestershire, and Rutland
Ethics Committee (UHL 09873). We compared different cohorts of
healthy and patient urine and serum samples as indicated in Results.
First, we used 25 archived IgAN urines (patients with diagnosed,
biopsy-proven IgAN) and 25 age and sex matched urine samples from
subjects without renal pathology, used as healthy controls, for urine
ELISAs as indicated. For comparison, we also used 14 archived urine
samples from patients with diagnosed non-IgAN renal disease as in-
dicated in Results. All healthy, IgAN and renal disease samples were
collected during scheduled clinical monitoring at the John Walls Renal
Unit, University Hospitals of Leicester NHS Trust. Second, we also used
25 biopsy-proven IgAN patients with low estimated glomerular filtra-
tion rate (eGFR) (25–53ml/min/1.73m2; group IgAN-1; mean age
43.2) and 25 biopsy-proven IgAN patients with normal eGFR
(103–141ml/min/1.73m2; group IgAN-2; mean age 29.4). The urine of
the 25 IgAN-1 and 25 IgAN-2 patients was a first-morning sample col-
lected at baseline as part of the NEFIGAN clinical trial [20] ahead of
randomization to drug or placebo. None were receiving im-
munosuppressive treatment at the time of urine collection and all were
European-Caucasian IgAN patients. The IgAN-1 and IgAN-2 urine
samples were compared initially with 15 healthy European-Caucasian
volunteers with no known kidney disease (mean age 33.5). These
samples were used as healthy controls for urine ELISA measurements as
indicated. From the 25 IgAN-1 and 25 IgAN-2 NEFIGAN clinical trial
[20] patients, we also used their matching serum samples for ELISA
measurements as indicated in Results. Serum samples were also
collected before pharmacological interventions. The NEFIGAN serum
samples were compared (ELISA) with 25 sex and age matched serum
samples collected from healthy subjects without renal disease at the
John Walls Renal Unit. All urine and serum samples were spun to re-
move cells and debris before freezing. Urine and serum samples were
frozen is smaller aliquots to minimize freeze-thaw cycles. Urine and
serum samples were slowly defrosted on ice before experimental pro-
cedures. All tissue and biofluid samples were collected, processed and
archived at the John Walls Renal Unit and kept at -80 oC. Finally, we
isolated peripheral blood mononuclear cells (PBMCs) from 7 healthy
donors using standard Histopaque-1077 (Merck) procedure. PBMCs
were taken from the buffy coat while granulocytes were obtained from
Histopaque pellets by lysing red blood cells with erythrocyte lysis buffer
(Roche) twice for 5min. All cells were cultured in RPMI plus 10% foetal
calf serum. Normal adult human mesangial cells and DAKIKI cell line
(human IgA+ B-cell lymphoma [21]) were obtained from ATCC.
3. Results
Shotgun LC-MS/MS (Q-Exactive) proteomics analysis on 500 μl of
albumin and IgG-depleted urine identified 325 proteins with high mass-
accuracy (10 ppm) and at least 2 unique peptides (Supplemental Tables
1 and 2). Albumin and IgG depletion of urine was utilised before pro-
teomics to reduce the concentration of the 2 most abundant protein
species in IgAN urine and thereby improve the dynamic range of pro-
tein identifications. All identified proteins and spectral counts are
provided in Supplemental Table 1. Full dataset peptide and protein
details are provided in Supplemental Table 2. Raw MS files have been
deposited and made freely accessible in Mendeley Data (https://bit.ly/
30Baxpc) to facilitate open data access. Proteomics measured an in-
crease in multiple immunoglobulins (including IgA) in IgAN urine to-
gether with an increase in complement C3 (Supplemental Table 1). The
classic marker of renal damage, cystatin-C (CSTC), was increased in
IgAN urine while uromodulin (UMOD) a biomarker of normal renal
function, was decreased as expected (Supplemental Table 1). Notably,
we were not able to completely remove albumin and IgG from urine
samples used for proteomics (Supplemental Table 1), likely due to
overwhelming proteinuria affecting IgAN patients.
We then submitted the 325 identified urine proteins to full gene
ontology (GO) analysis [22] which includes “Biological process”, “Mo-
lecular function” and “Cellular component” GO categories, to isolate the
main protein classifications in our identified urine proteome
(Supplemental Fig. 1). Proteins classified by GO as “Extracellular”,
dominated both healthy and IgAN urine (Supplemental Fig. 1E-F). In-
flammation and proteolysis-related proteins accumulated in IgAN urine
while healthy urine was enriched in adhesion and receptor-binding
factors (Supplemental Fig. 1E-F). Amongst multiple proteins that have
not been reported in IgAN previously (Supplemental Table 1), we noted
19 lysosomal proteins in urine (Fig. 1A) including cathepsins (CTSB,
CTSC, CTSD, CTSZ), proteolytic inhibitors (cystatins; CSTA, CSTB,
CST3, CST6) as well as other less studied proteins (ACPP, ARSA, NCP2,
PEBP4). The presence of lysosomal proteins might be the result of
exosome secretion in urine as previously noted [23].
Our attention was captured by PEBP4 (Fig. 1A and Supplemental
Table 1) a likely lysosomal protein [14] with unknown renal function.
This relatively understudied protein is possibly secreted [24] and might
act as a cell survival factor in different tumours, most notably (given the
involvement of B-cells in IgAN) B-cell lymphoma [15,25–27]. Elevation
of PEBP4 in IgAN urine was validated first by dot-blot (Fig. 1B-C) in
archived healthy and IgAN urines (from the Leicester renal bioarchive)
followed by ELISA (Fig. 1D). Urine ELISA-estimated concentrations
were corrected to urine creatinine (values shown in Supplemental
Fig. 2A) as per standard experimental practice [19]. For comparison,
we examined cathepsin Z (CTSZ; Fig. 1E), a classic lysosomal protein
with unknown function in IgAN that we also detected in urine by
proteomics, albeit with few spectra (Supplemental Table 1). CTSZ was
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not significantly altered in the same urine samples (Fig. 1E) indicating
that increased urinary PEBP4 is likely not due to random release of
tissue proteins in IgAN urine as a result of proteinuria. To determine the
specificity of urinary PEBP4 excretion in IgAN we measured PEBP4 in
the urine of 14 non-IgAN chronic kidney disease urine samples. PEBP4
was undetectable in 11 of 14 samples but highly elevated in 3 samples
(Fig. 1F; “type-2 diabetes”, “chronic obstructive nephropathy” and
“focal segmental glomerulosclerosis”) indicating that urinary PEBP4
excretion might not be exclusive to IgAN but is perhaps related to
kidney damage or inflammation. The expression of PEBP4 in other
renal diseases needs further investigation in larger patient cohorts.
To further examine urinary excretion of PEBP4, we validated its
increase in a separate cohort of 50 IgAN urine samples collected at the
beginning of the NEFIGAN clinical trial [20] and before pharmacolo-
gical intervention (Fig. 1G). ELISA-estimated PEBP4 concentrations
were creatinine-corrected and creatinine values for these samples are
shown in Supplemental Fig. 2B. To determine whether there was any
relationship between renal function and PEBP4 in urine, IgAN samples
from the NEFIGAN cohort were split according to baseline patient es-
timated glomerular filtration rate of creatinine (eGFR; shown in
Supplemental Fig. 2C). eGFR is used as a measure of renal filtration and
values < 60ml/min/1.73m2 point towards impaired kidney function.
25 IgAN patients had low eGFR (25–53ml/min/1.73m2; IgAN-1 group
Fig. 1G) while 25 IgAN patients had normal range eGFR (103–141ml/
min/1.73m2; IgAN-2 Fig. 1G). ELISA validated the significant increase
of PEBP4 in IgAN urine and notably, PEBP4 was significantly higher in
patients with low eGFR (IgAN-1 Fig. 1G). In total 49 out of 50 IgAN-1
and IgAN-2 patients had detectable PEBP4 in their urine (4–85 ng/ml).
PEBP4 was also detected in healthy and IgAN human serum and com-
paratively at higher concentrations than in urine (Fig.1H; 102-
1,526 ng/ml). Again, PEBP4 was significantly increased in IgAN serum
with a clear elevation in IgAN-1 patients (Fig. 1H). Finally while there
was no significant correlation between PEBP4 and protein concentra-
tion in IgAN urine (Fig. 1I), indicating that PEBP4 is likely not related to
non-selective proteinuria, there was a significant negative correlation
between PEBP4 and eGFR in IgAN patients (Fig.1J; r= -0.35, p= 0.01)
Fig. 1. PEBP4 was identified by proteomics in urine and is increased in IgAN urine and serum. A: LC-MS/MS Proteomics analysis of healthy donor and IgAN
patient urine identified 19 lysosomal proteins including PEBP4. Lysosomal proteins were isolated from identified urine proteins using gene ontology and are
presented as a colour-coded protein-protein interaction network (yellow and red are upregulated in IgAN urine as indicated, while grey are unchanged between
healthy and IgAN urine. Also see Supplemental Fig. 1 and Supplemental Table 1. B–C: PEBP4 levels were compared in healthy and IgAN urines using dot-blot on a
nitrocellulose membrane and antibodies against PEBP4 (B) and quantified by densitometry (C). 1 μl of urine was used per dot. D-E: PEBP4 (D) and CTSZ (E) levels
were compared in a cohort of healthy or IgAN urines using ELISA. ELISA values were corrected to urine creatinine concentration measured on the same urine
samples. Correcting ELISA measurements to urine creatinine is standard practice to account for differences in urine concentration and hydration. Statistical com-
parisons were performed using t-test. t-test p-values are shown on graphs; ns: not significant. F: Urine PEBP4 estimation by ELISA (creatinine-corrected) in healthy
donors versus patients with non-IgAN renal disease. The 3 urine samples with high PEBP4 were from a patient with type-2 diabetes, one with chronic obstructive
nephropathy and one with focal segmental glomerulosclerosis. t-test p-value shown. G-H: PEBP4 levels measured in healthy donor or IgAN patient urine (G) and
serum (H). PEBP4 urine levels were corrected to urine creatinine as above. Two groups of IgAN urine and serum were used (IgAN-1 n= 25 and IgAN-2 n= 25) from
biopsy-diagnosed IgAN patients registered in the NEFIGAN clinical trial. Patients in the IgAN-1 group had low eGFR (25–53ml/min/1.73m2) while IgAN-2 group
had normal eGFR (103–141ml/min/1.73m2). eGFR<60 indicates decline in renal function. Statistical estimations were performed using ANOVA and Fisher LSD
post-hoc test comparing healthy subjects versus either IgAN-1 or IgAN-2 patients. Fisher LSD p-values are shown. I: No significant correlation between PEBP4 urine
levels and urine protein concentration (all values are creatinine-corrected). J: Negative and significant correlation of patient PEBP4 urine levels (creatinine-cor-
rected) with patient eGFR (eGFR from NEFIGAN IgAN-1 and IgAN-2 patients; see Supplemental Fig. 2C). Statistical p and r values were calculated with Pearson
correlation. K–N: IgA and IgG levels were measured in the healthy donor or IgAN (IgAN-1 and IgAN-2 cohorts) urine and serum as indicated. Urine values are
creatinine-corrected. Statistical estimations were performed using ANOVA and Fisher LSD test comparing healthy subjects versus either IgAN-1 or IgAN-2 patients.
Fisher LSD p-values are shown. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
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suggesting that urinary PEBP4 is increased with more kidney damage.
Thus, PEBP4 is a soluble protein present in serum and urine, is upre-
gulated in IgAN and its elevation correlates with reduced kidney
function.
Similar to PEBP4, IgA and IgG were elevated in IgAN urine and were
higher in IgAN-1 patients (Fig. 1K-L). IgA was also increased in the
serum of IgAN patients (Fig. 1M; no difference between IgAN-1 and
IgAN-2 cohorts), while serum IgG was consistent across healthy and
IgAN donors (Fig. 1N). Many previous studies have shown elevated
circulating and urine IgA (and IgA1 immune-complexes) in IgAN pa-
tients [3,4,28]. There was a greater number of male IgAN patients in
the NEFIGAN cohort (36 males vs 14 females), but no gender-specific
difference in urinary PEBP4 (Supplemental Fig. 2D). In contrast, IgAN-1
patients (low eGFR) had significantly higher mean age (43.2 years) in
comparison to IgAN-2 patients (normal eGFR) and 29.4 years
(Supplemental Fig. 2E). This might explain differences in renal function
and as a result differences in urine PEBP4. Finally, while asymptomatic
urinary tract infections cannot be categorically excluded, we found no
difference in urine endotoxin in healthy or IgAN patients (Supplemental
Fig. 2F). Urinary tract infections might alter the immune response and
as a result affect protein composition in urine ( especially im-
munoglobulins).
Next, we set out to determine whether PEBP4 was expressed in the
kidney. IgAN and healthy (transplant donors with no renal disease)
kidney biopsies from the Leicester renal archive were immunostained
with PEBP4 together with different proteins (Fig. 2). First, PEBP4 co-
localised with a proportion of IgA immunostaining (Fig. 2A; PEBP4 red,
IgA green) in IgAN glomeruli and in the lumen of renal tubules
(Fig. 2A). Luminal staining perhaps explains the release of PEBP4 in
urine. While this strong and sporadic PEBP4 immunoreactivity was not
found in healthy biopsies (Fig. 2B), weak PEBP4 staining was seen in
IgAN and healthy renal tubules (Fig. 2A-B) consistent with reported
ubiquitous staining of PEBP4 in human tissues (www.proteinatlas.org).
Second, in IgAN PEBP4 was in close proximity with vimentin+ cells in
glomeruli (Fig. 2C; predominantly mesangial and endothelial cells) but
the two proteins did not colocalise (Fig. 2C). Fig. 2D depicts healthy
biopsies. Third, PEBP4 did not colocalise with CD64+ phagocytes
(Fig. 2E; CD64 green; CD64 will primarily stain macrophages and
neutrophils) decorating glomeruli and inflammatory IgAN lesions in the
kidney interstitium (Fig. 2E). Fig. 2F depicts healthy biopsies.
Closer examination of high-magnification IgAN images (Fig. 2G;
IgA-PEBP4 and Fig. 2H; PEBP4-vimentin) revealed that PEBP4 was lo-
calised in structures that resemble blood vessels immediately adjacent
to glomeruli and thus most likely glomerular arterioles (Fig. 2G-H; the
endothelial layer of the vessel in Fig. 2H is stained green with vi-
mentin). Notably, identification of PEBP4 within blood vessels was very
rare, perhaps because of the dynamic nature of blood circulation as well
as tissue embedding and cutting conditions that are outside our tech-
nical control. These examples indicate that PEBP4 is likely infiltrating
from the circulation. The upregulation of PEBP4 in IgAN serum
(Fig. 1H) further supports the conclusion that PEBP4 might enter the
kidney from the peripheral circulation.
The relationship of PEBP4 with IgA, the key pathogenic factor in
IgAN and a marker of B-cells [29,30], was surprising. To investigate this
further we stained tissue biopsies for CD19, a classic marker of B-cells
(Fig. 3A). PEBP4 colocalised with CD19 and IgA in IgAN glomeruli and
in the lumen of tubules (Fig. 3A). Areas with IgA staining alone
(without CD19 or PEBP4 immunoreactivity) represent mesangial IgA
deposition as per typical IgAN histopathology. Thus, strong PEBP4
immunopositivity is likely related to infiltrating CD19+/IgA+ B-cells.
Fig. 2. PEBP4 immunofluorescence in renal
biopsy specimens. A-B: Sporadic clusters of strong
PEBP4 immunoreactivity (red) were observed in
IgAN glomeruli (A; glom) and in the lumen of IgAN
tubules (A; tub). In IgAN specimens (A) PEBP4 (red)
and IgA (green) colocalise in glomeruli (glom) and in
the lumen of tubules (tub). Note that not all IgA
immunoreactivity is associated with PEBP4. In
healthy biopsies (B), there was only weak PEBP4
immunoreactivity in renal tubules (also seen in
IgAN), but no evidence of the strong, sporadic PEBP4
immunostaining seen in IgAN specimens. C-D: PEBP4
(red) in IgAN glomeruli (C) does not colocalise with
vimentin (green). PEBP4 is strongly immunoreactive
in the lumen of IgAN renal tubules (C). Healthy
kidneys (D) have vimentin staining in glomeruli (D)
but there is little PEBP4 immunostaining. Vimentin
stains mainly mesangial and endothelial cells. E-F:
PEBP4 (red) does not colocalise with
CD64+ phagocytes (green) in IgAN biopsies (E). Few
CD64+ cells can be seen in IgAN glomeruli (E) but
many accumulate in interstitial lesions (E; les). Weak
CD64 staining (few isolated cells) can be seen in
healthy kidney biopsies (F). G-H: In two IgAN spe-
cimens stained with either IgA (G) or Vimentin (H)
we noted strong PEBP4 immunostaining within
structures that resemble glomerular arterioles (Art),
next to glomeruli. These structures are depicted in
white dashed boxes and magnified as shown. (For
interpretation of the references to color in this figure
legend, the reader is referred to the Web version of
this article.)
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Fig. 3. Association of PEBP4 with CD19 and IgA in IgAN lesions and B-cell related proteins in urine. A: In few IgAN specimens PEBP4 (red), colocalised with
the B-cell marker CD19 (blue) and IgA (green) in glomeruli and in the lumen of IgAN tubules. White dashed boxes (A) depict areas that are magnified in adjacent
images. Note that not all IgA+ areas in IgAN glomeruli (A) are PEBP4+/CD19+. Single IgA immunostaining likely depicts typical mesangial IgA deposits in IgAN. B:
Healthy donor biopsies have weak immunostaining as before. C-J: Levels of different soluble factors involved in B-cell activation and IgA class-switch are estimated
by ELISA in healthy and IgAN urine. BAFF (C) and its receptors BCMA (D) and TACI (E) were increased in IgAN urine, especially in IgAN-1 patients (low eGFR,
reduced renal function group). BAFF-R (F) was unchanged in urine. Urinary TGFB1 (G) is significantly different between healthy and IgAN-2 subjects but not between
healthy and IgAN-1. IFNG (H) was unchanged. Secretory IgA (sIgA; I) was increased in IgAN urine while J-chain (J) was unchanged. All values are creatinine
corrected as before. Statistical analysis was performed using ANOVA and Fisher LSD post-hoc comparisons, testing IgAN-1 and IgAN-2 groups versus healthy subjects;
post-hoc p-values are indicated on graphs. ns; not significant. Please note that for in-house made sIgA ELISA (I), differences were estimated by normalised OD rather
than absolute concentrations [17]. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
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Nevertheless, it is important to note that while PEBP4 was increased
(ELISA) in the overwhelming majority of IgAN urines and sera tested, as
well as in few healthy samples (Fig. 1B-D and Fig. 1G-H), we were only
able to find strong PEBP4 immunoreactivity and costaining with CD19
and IgA in just 3 out of 8 IgAN biopsies. In the remaining biopsies and
in healthy controls (Figs. 3B and 2B, D, F), PEBP4 was weakly expressed
in renal tubules, in agreement with (antibody-based) expression of
PEBP4 in most tissues (Human Protein Atlas; www.proteinatlas.org).
The presence of circulating CD19+ B-cells infiltrating IgAN kidneys has
been previously documented in 3 studies [8,31,32] but surprisingly
their exact immunophenotype or function in IgAN kidney has not been
examined in detail thus far, perhaps because they are few and hard to
identify in the tissue. IgAN kidney biopsies are also very small making
such efforts challenging.
Another disease with substantial B-cell involvement is systemic
lupus erythrematosus (SLE). The most common pathological manifes-
tation of SLE patients is nephritis (lupus nephritis), characterised by
renal accumulation of immune complexes (including IgA) and B-cell
infiltration [33,34]. To this end, we found PEBP4-IgA costaining on
kidney biopsies from 2 SLE patients with nephritis (Supplemental
Fig. 3). Most of the sporadic PEBP4-IgA colocalisation was seen in af-
fected glomeruli and in the interstitium between renal tubules, but
unlike IgAN specimens, not in the lumen of tubules.
The association of PEBP4 with IgA and CD19 prompted us to ex-
amine more B-cell related proteins in IgAN urine, especially those in-
volved in IgA class-switch and expression (Fig. 3C-J). Like PEBP4, B-cell
activating factor (BAFF) [12] was significantly increased in the urine of
IgAN-1 patients (low eGFR) but not IgAN-2 patients (normal eGFR)
(Fig. 3C). In contrast to PEBP4, BAFF was unchanged in serum
(Supplemental Fig. 2G) indicating the complexity in soluble factor
regulation in biofluids and the likely importance of urine as a more
selective pool for bioactive factors. The B-cell-specific BAFF/APRIL
receptor BCMA [35] (B-cell maturation antigen or TNFRSF17) together
with TACI (transmembrane activator and CAML interactor or
TNFRSF13B) another BAFF/APRIL receptor expressed on B- and T-cells
[36], were increased in IgAN urine and further elevated in IgAN-1 (low
eGFR) patients (Fig. 3D-E). TACI was very low in IgAN-2 samples. In
contrast to BCMA and TACI, the third specific BAFF receptor, BAFF-R
(or TNFRSF13C), was unchanged between healthy and IgAN donors
(Fig. 3F). We also examined two T-cell derived cytokines TGFβ1 and
IFNγ, also involved in immunoglobulin regulation by B-cells. TGFβ1
(IgA class-switch) was present in healthy and IgAN urine and was
modestly increased in IgAN-2 patients (Fig. 3G), while low levels of
IFNγ (IgG2 expression) were detected in urine but the cytokine was
unchanged between healthy and IgAN samples (Fig. 3H). Finally, while
secretory IgA (sIgA) was increased in both IgAN-1 and IgAN-2 urine
(Fig.3I), J-chain link protein (necessary for sIgA mucosal secretion) was
unchanged (Fig. 3J). This might be due to the fact that J-chain in-
corporated in sIgA is masked by the associated IgA molecules (as it is
not in free form) and perhaps explains why it is not consistently de-
tected by ELISA in urine. Increased sIgA in the serum and urine of IgAN
patients has been routinely reported and is likely related to IgAN pa-
thophysiology [37,38]. The presence of sIgA in normal urine is also
expected (and in high concentrations) given its presence in the urinary
mucosa.
In summary, alongside PEBP4, classic factors associated with IgA
class-switch and IgA expression on B-cells are elevated in IgAN urine. It
is important to note however that apart from the proteins mentioned
above, we also tested the urine for other B-cell relevant proteins, in-
cluding CD19, APRIL, IL6, IL10 and CD138 (marker of plasma B-cells)
but all were undetectable in either healthy or IgAN urine. Similarly,
urine proteomics analysis did not detect specific B-cell factors or B-cell
“CD” markers but this might be related to the limit of LC-MS/MS de-
tection (such cellular markers are not likely to be soluble and abundant
in biofluids) and the fact that urine samples were spun to remove cel-
lular debris before processing.
The possible immune-related or kidney function of PEBP4 is un-
known. The Human Protein Atlas reports ubiquitous staining of PEBP4
in most normal human organs and highest expression in tonsil and
spleen, tissues high in B-cells. Similarly, sequence of different cell lines
(and published work - [27]) suggests highest PEBP4 expression in
myeloma B-lymphocytes (NCBI BioProject PRJNA183192; www.
proteinatlas.org). To obtain an unbiased overview on possible mole-
cular functions of PEBP4, we examined its expression in published
microarray datasets derived from the European Bioinformatics Institute
(EBI) ArrayExpress public repository. While PEBP4 was differentially
regulated in multiple cancer-related studies, we found that it was up-
regulated in a more relevant microarray dataset derived from the classic
monocytic cell line THP1 stimulated with 100 ng/ml IFNγ for 3 days.
(ArrayExpress EBI; E-MTAB-5917). Notably, PEBP4 was weakly upre-
gulated in THP1 cells only following stimulation with IFNγ and not
after LPS or combined LPS-IFNγ stimulation. 1937 genes were upre-
gulated alongside PEBP4 following IFNγ stimulation (Supplemental
Fig. 4; differential expression data was downloaded from E-MTAB-
5917). We then used protein-protein interaction network analysis to
find first-degree neighbours of PEBP4, i.e. IFNγ-induced genes in THP1
cells directly interacting with PEBP4 (Fig. 4A). The PEBP4 interactome
(Fig. 4A) contains 41 inflammation-related genes including the TNF-
family cytokine TRAIL (TNFSF10), B-cell proteins KMO and ADAM28,
as well as MAPK1 (ERK2 MAP-kinase) and the TGF-family growth
factor BMP1 (Fig. 4A). Similar to urine proteomics, the 2 top GO
functional enrichments for this gene cluster include “Extracellular re-
gion” (Fig. 4B) and “Lysosome” (Fig. 4C). Lysosomal proteins cathepsin-
B (CTSB) and aryl sulfatase-A (ARSA), were also found in IgAN urine
(Fig. 1A and Supplemental Table 1).
In cell culture experiments, an IgA+ monoclonal B-cell line (DAKIKI
human B-cell lymphoma [21]) expressed higher levels of PEBP4 in
comparison to human mesangial cells (Fig. 4D). PEBP4 protein was also
more abundant in peripheral PBMCs in contrast to granulocytes from
the same donors (Fig. 4E). When cultured human PBMCs were stimu-
lated for 24 h with different cytokines (Fig. 4F-G), IFNγ caused a clear
increase in the secretion of PEBP4 in the PBMC culture medium from 7
healthy donors (Fig. 4G) but without causing notable alteration in
PEBP4 expression in the same PBMC cellular lysates (Fig. 4F; re-
presentative blot). Thus, PEBP4 is likely a secreted protein and its se-
cretion by human PBMCs in vitro is enhanced by IFNγ. It is important to
highlight that urinary IFNγ was not increased in IgAN patients (Fig. 3H)
and thus we cannot speculate whether there is a functional link be-
tween IFNγ and increased soluble PEBP4 in IgAN in vivo.
4. Discussion
PEBP4 is a ubiquitous and evolutionary conserved but scarcely
studied protein that like the other PEBP family members (PEBP1-4),
potentially binds phosphatidylethanolamine and might act as a serine
protease inhibitor [14]. 15 years ago, mechanistic experiments that
have not received further attention, indicated that PEBP4 is mainly
lysosomal and responds to TNFα treatment by translocating to the cell
membrane where it binds with ERK kinase MEK1 and inhibits TNFα
induced activation of ERK via RAF1 and MEK1 [14,15]. More recent
work has shown over-expression of PEBP4 in multiple tumours and a
likely anti-apoptotic function that promotes cancer development and
metastasis [15,25–27]. The protein might also participate in epithelial-
to-mesenchymal transition (EMT) in small cell lung cancer by activating
the sonic hedgehog pathway [25].
The possible IgAN function of PEBP4 is unknown. We found that
PEBP4 was consistently upregulated in IgAN urine and serum. The
possibility that this protein might be a disease biomarker needs to be
examined further and prospectively to understand if it is linked to the
risk of IgAN progression. The possible sensitivity of PEBP4 is also un-
known but it needs to be examined further given that PEBP4 is also
found in few healthy serum and urine samples. Future studies in larger
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patient cohorts combining IgAN and other renal diseases are necessary
given that PEBP4 was increased in the urine of 3 non-IgAN patients as
well as in 2 lupus nephritis biopsies, the latter characterised by B-cell
infiltration in the kidney [33,34]. Elevated PEBP4 might not be ex-
clusive to IgAN but it might be a marker of renal damage or perhaps a
by-product of immune activation that involves B-cells.
PEBP4 sporadically colocalised with IgA and CD19 in few IgAN
biopsies indicating that it might be related to circulating IgA+ B-cells
[29,30] infiltrating IgAN lesions. The origin of PEBP4 from the circu-
lation was further supported by its localisation within glomerular ar-
terioles and its upregulation in IgAN serum. In addition, the increase in
urinary PEBP4 coincided with an increase in IgA class-switch molecules
BAFF, BCMA, TACI and TGFβ1 in IgAN urine, indicating B-cell acti-
vation towards IgA expression in IgAN patients.
Nevertheless, linking PEBP4 with B-cell activity and function in
IgAN tissue and urine was not conclusive. For instance, in contrast to
BAFF, BCMA and TACI, BAFF-R (which is BAFF-specific) was
unchanged between healthy and IgAN subjects, while we failed to de-
tect by ELISA other key B-cell proteins in urine, including CD19 and IgA
class-switch cytokines APRIL, IL6 and IL10. It is possible that PEBP4 is
linked to a specific B-cell response taking place in IgAN and involving
only specific factors (i.e. BAFF, BCMA, TACI), but it is also possible that
some cytokines and B-cell proteins are not abundant and therefore
difficult to detect. Thus, we provide evidence that PEBP4 is associated
with IgA+/CD19+ cells as well as B-cell factors in urine, but more work
is needed in future studies to characterise the exact phenotype of
PEBP4+ cells in IgAN and perhaps in other renal pathologies.
Moreover, although B-cells have been extensively studied in relation
to IgAN in blood and peripheral tissues [8,39,40], infiltration of cir-
culating B-cells in IgAN kidneys has been reported in just 3 studies
[8,31,32]. Their possible regulation and immunological function in the
kidney is incompletely understood, but they might target autoreactive
immune-complexes [8]. IgA class-switch factors and related mechan-
isms in IgAN are also gaining specific attention [41–43] mainly as
Fig. 4. Investigating PEBP4 expression in cells. A-C: 41 PEBP4 first neighbour genes (PEBP4 interactome; A) were isolated from the protein-protein interaction
network of upregulated genes derived from a published microarray analysis of THP1 cells stimulated with IFNγ (100 ng/ml) for 3 days (E-MTAB-5917; ArrayExpress
EBI; see Supplemental Fig. 4). The PEBP4 interactome (A) is enriched in “Extracellular region” and “Lysosome” gene ontology (GO) categories and relevant genes are
isolated in (B) and (C) respectively. Protein-protein interaction networks were created using data from StringDB and designed in Cytoscape. Gene Ontology (GO) was
analysed using BinGO in Cytoscape. D: PEBP4 expression in human primary mesangial cells and DAKIKI cells (human IgA+ B-cell lymphoma) was examined in cell
lysates by immunoblotting. Cells were cultured for 3 days before lysis in 0.2% SDS. 20 μg of cellular protein was immunoblotted. β-Actin served as the loading
control. E: Granulocytes and PBMCs were isolated from human EDTA-treated blood using standard protocol. Cells were cultured for 24 h before lysis. 20 μg of cellular
protein was immunoblotted. PBMC lysates contain more PEBP4 while granulocyte lysates are enriched in myeloperoxidase (MPO; neutrophil marker). A re-
presentative blot is shown. F-G: PBMCs were isolated, cultured and stimulated for 24 h with either 1 μg/ml LPS or 150 ng/ml IL1β, IL10 and IFNγ. Control PBMCs
were unstimulated (Con). PBMC lysates were immunoblotted for PEBP4 (F) while the PBMC culture medium was used to detect PEBP4 by ELISA (G). Statistical
analysis was performed using ANOVA and Fisher LSD post-hoc comparisons, testing the effect of different cytokines versus unstimulated cells (Con); post-hoc p-values
are indicated on graphs. ns; not significant. IFNγ caused a clear increase in the release of PEBP4 in the PBMC culture medium 24 h after stimulation (G) while LPS
reduced PEBP4 (close to significant). Note that there was no observable change in PEBP4 levels in PBMC lysates (F).
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regulators of IgA overexpression by B-cells [44] and as possible ther-
apeutic targets, with a particular focus on BAFF and APRIL [36]. Exact
multi-marker phenotyping and bioactivity profiling of circulating,
mucosal or kidney infiltrating B-cells in IgAN has not been performed
thus far using high-throughput transcriptomics or proteomics ap-
proaches but it is an important area for future research and clinical
work. Such efforts might inform therapies targeting the bioactivity of B-
cells in IgAN. Recent studies are moving towards this direction [8].
The possible function of PEBP4 on B- or other immune cells is also
unknown and due to lack of knowledge about this protein it is chal-
lenging to speculate. Given the function of PEBP-family proteins in
binding phosphatidylethanolamine [14], PEBP4 might bind secreted
IgA coming in contact with the cellular membrane and this could ex-
plain the colocalisation of IgA and PEBP4 in tubules and their soluble
coexpression in serum and urine. Given its anti-apoptotic role in B-cell
lymphoma [27], PEBP4 might be involved in the survival and/or
maintenance of B-cells in IgAN. Interestingly, by searching high-
throughput gene expression data in published microarray datasets, we
found that PEBP4 was upregulated in monocytic THP1 cells following
stimulation with IFNγ. More importantly, IFNγ stimulation caused a
consistent secretion of PEBP4 from cultured human PBMCs. Thus,
PEBP4 is a secreted soluble protein - an essential property for a bio-
marker candidate or bioactive factor - and responds to IFNγ stimulation.
The possible soluble/secreted function of PEBP4 needs to be studied in
future mechanistic studies to understand whether it is bioactive in IgAN
and if bioactivity is linked to IFNγ inflammatory regulation. The role of
IFNγ in IgAN has been examined since the 1990's but not much is
known other than the fact that the cytokine is increased in IgAN PBMCs
[45], including B-cells [32], and that it accumulates in IgAN lesions
[46,47]. The function of IFNγ in IgAN is an interesting area for further
work, especially because the cytokine stimulates the production of IgG2
by B-cells [48,49].
PEBP4 was identified here fortuitously while we were developing
methodology to analyse small quantities of IgAN urine by proteomics.
Modern high-throughput proteomics can play an important role in the
discovery of pathological bioactive proteins and disease biomarkers. In
comparison to transcriptomics, which measure rapidly fluctuating
mRNA changes, proteomics can quantify proteotypic changes and
protein accumulation taking place in diseased tissues and can measure
cellular tissue proteins, as well as secreted and soluble tissue proteins in
the extracellular environment and in biofluids [16]. Urine is an ex-
cellent reservoir for soluble bioactive proteins and likely biomarkers
and it is encouraging that a number of recent studies have targeted
IgAN urine using proteomics [23,50–52]. Although most studies have
used large, unpractical volumes of highly concentrated urine and
complicated protocols for protein processing, we believe that it is im-
portant to focus future efforts on small urine volumes coupled to ultra-
high resolution mass-spectrometers in order to increase the clinical
application of urine proteomics using current technology. An important
implication of our work is that non-invasive urinary analysis (either by
proteomics or by targeting specific protein markers) could be utilised to
monitor immunological bioactivity as well as response to therapeutic
strategies in IgAN and other kidney diseases.
Taken together, PEBP4 is a new soluble IgAN-related protein. Its
concentration increases in serum and urine of IgAN patients in corre-
lation to kidney damage and is likely associated with IgA+ B-cells in-
filtrating the IgAN kidney. The role of B-cells in kidney damage or tissue
inflammation in IgAN is incompletely understood. The likely function
of PEBP4 in IgAN pathology is unknown but its upregulation in IgAN
urine and serum, and its relationship with IgA and B-cells warrants
further investigation. PEBP4 might be a disease marker or a soluble
bioactive factor in IgAN.
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